Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses | HIV.gov

Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses | HIV.gov

Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses

July 24, 2017 - Crossposted from NIAID Newsroom

TOPICS: NIAID, NIH, Research, Vaccine

Results from an early-stage clinical trial called APPROACH show that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against HIV in healthy adults. The APPROACH findings, as well as results expected in late 2017 from another early-stage clinical trial called TRAVERSE, will form the basis of the decision whether to move forward with a larger trial in southern Africa to evaluate...[READ MORE]